News
TRAX ▼ -0.7% - First Tracks Biotherapeutics, Inc.
TRAX ▼ -0.7% - First Tracks Biotherapeutics, Inc.
$TRAX - First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026
11-OCT-2026 04:00 PM ET
Share this post
More filings for $TRAX
TRAX - First Tracks Biotherapeutics, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026TRAX - First Tracks Biotherapeutics, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026TRAX - First Tracks Biotherapeutics, Inc. - SEC Filing Update (06-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 6, 2026$TRAX SEC Filing Update (28-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 28, 2026
View full $TRAX filing history →💬 Comments
Loading comments…
Leave a comment